Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1A Dose Escalation and Phase 1B Expansion Study to Evaluate the Safety and Tolerability of ETC-1907206 in Combination With Dasatinib in Advanced Haematologic Malignancies

NCT03414450 is registered in ClinicalTrials.gov with EDDC (Experimental Drug Development Centre), A*STAR Research Entities as lead sponsor.

NCT NCT03414450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03414450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1A Dose Escalation and Phase 1B Expansion Study to Evaluate the Safety and Tolerability of ETC-1907206 in Combination With Dasatinib in Advanced Haematologic Malignancies
Lead sponsor
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Phase
Phase 1
Overall status
Withdrawn
Start date
April 25, 2018
Completion date
February 28, 2023
Enrollment
0 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia accelerated phase (cml-ap, ph+), chronic myeloid leukemia blast crisis (cml-bc, ph+), ph+ acute lymphoblastic leukemia (ph+all), ph- acute lymphoblastic leukemia (ph-all)